Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Oncology

Expert Opinion / Conference Coverage · July 25, 2013

Biomarkers Begin the Breakthrough in Non–Small Cell Cancer

Written by
Jean-Yves Douillard MD, PhD

 

 Save  Recommend
 Share

Additional Info

  1. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer patients. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8000. J Clin Oncol 31, 2013(suppl; abstr 8000).

  2. Johnson BE, Kris MG, Berry LD, et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8019. J Clin Oncol 31, 2013(suppl; abstr 8019).

  3. Peters S, Weder W, Meldgaard P, et al. The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 7514. J Clin Oncol 31, 2013(suppl; abstr 7514).

  4. Mok T, Wu YL, Lee JS, et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib and chemotherapy. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8021. J Clin Oncol 31, 2013(suppl; abstr 8021).

  5. Reck M, Kaiser R, Mellemgaard A, et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract LBA8011. J Clin Oncol 31, 2013(suppl; abstr LBA8011).

  6. Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer after failure of first-line chemotherapy. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8034. J Clin Oncol 31, 2013(suppl; abstr 8034).

  7. Bepler G, Williams CC, Schell MJ, et al. Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8001. J Clin Oncol 31, 2013(suppl; abstr 8001).

  8. Rittmeyer A, Scherpereel A, Gorbunova VA, et al. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer on overall survival of patients on the AVAPERL (MO22089) phase III randomized trial. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8014. J Clin Oncol 31, 2013(suppl; abstr 8014).

  9. Okano Y, Ando M, Asami K, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small cell lung cancer who have wild-type or mutant epidermal growth factor receptor: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8006. J Clin Oncol 31, 2013(suppl; abstr 8006).

  10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.

  11. Garassino MC, Martelli O, Bettini A, et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type EGFR. Paper presented at: the American Society of Clinical Oncology; June 1-5, 2012; Chicago IL. Abstract LBA7501. J Clin Oncol 30, 2012(suppl; abstr LBA7501).

  12. Wu YL, Zhou C, Hu C-P, et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib versus gemcitabine/cisplatin as first-line treatment for Asian patients with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 8016. J Clin Oncol 31, 2013(suppl; abstr 8016).

  13. Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013;14(8):777-786.

  14. Butts CA, Socinski MA, Mitchell P, et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. Paper presented at: the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago IL. Abstract 7500. J Clin Oncol 31, 2013(suppl; abstr 7500).

Further Reading

Most Read This Week

Recently Updated